Dr. Li Shan 单利
Chief Physician, Associate Professor
Department of Medical Oncology, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, chemotherapy, and molecular targeted therapy for thoracic tumors, with a special focus on lung cancer.
Dr. Shan graduated from Xinjiang Medical College in 1985 and has worked in oncology since 1989. As Director of Internal Medicine I and the Medical Affairs Department, Dr. Shan specializes in lung cancer diagnosis, chemotherapy, and targeted therapy. Research interests include EGFR mutations, ERCC-1 expression, and clinical trials for advanced non-small cell lung cancer.
Professional roles
- Executive Committee Member, Clinical Oncology Collaboration Center, China Anti-Cancer Association
- Member, National Chemotherapy Professional Committee
- Executive Committee Member, Western China Lung Cancer Collaboration Center
- Council Member, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Shan Li). Papers usually list the name as Li Shan or Shan L.
Selected publications
32 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Exp Lung Res, 2021 (senior author): ACTL6A promotes the growth in non-small cell lung cancer by regulating Hippo/Yap pathway. PubMed 33896314
- Onco Targets Ther, 2019 (senior author): The Biological-Behavioral Effect Of Neuritin On Non-Small Cell Lung Cancer Vascular Endothelial Cells Via VEGFR And Notch1. PubMed 31819478
- Biomed Pharmacother, 2019 (senior author): miR-133b inhibits cell proliferation, migration and invasion of esophageal squamous cell carcinoma by targeting EGFR. PubMed 30594787
- Onco Targets Ther, 2018 (senior author): Expression and functional characterization of FOXM1 in non-small cell lung cancer. PubMed 29928129
- Med Sci Monit, 2017 (senior author): Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population. PubMed 28442702
- Int J Clin Exp Med, 2015 (senior author): Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer. PubMed 26885207
- Onco Targets Ther, 2015 (senior author): Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. PubMed 26261421
- Zhongguo Fei Ai Za Zhi, 2013 (senior author): [Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs]. PubMed 23769345
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion